Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes

NEW YORK–(BUSINESS WIRE)– Bristol-Myers
Squibb Company (NYSE:BMY) today announced that it has agreed to sell
$1.5 billion of senior unsecured notes: $750 million in aggregate
principal amount of 1.600% notes due 2019 and $750 million in aggregate
principal amount of 3.250% notes due 2027, in an underwritten public
offering.

Goldman, Sachs & Co., Morgan Stanley & Co. LLC, Merrill Lynch, Pierce,
Fenner & Smith Incorporated, Citigroup Global Markets Inc. and J.P.
Morgan Securities LLC are acting as joint book-running managers for the
offering.

Bristol-Myers Squibb intends to use the proceeds from the offering to
fund its share repurchase program and for general corporate purposes.

The final prospectus supplement and accompanying prospectus, when
available, may be accessed through the SEC’s website at https://www.sec.gov/.
Alternatively, the issuer, the underwriters or any dealer participating
in the offering will arrange to send you the prospectus and prospectus
supplement if you request it by calling Goldman, Sachs & Co. at
1-866-471-2526, Morgan Stanley & Co. LLC at 1-866-718-1649 or Merrill
Lynch, Pierce, Fenner & Smith Incorporated at 1-800-294-1322.

These securities are offered pursuant to a registration statement that
has become effective under the Securities Act of 1933, as amended. These
securities are only offered by means of the prospectus supplement and
prospectus relating to the offering. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any offer or sale of these securities in any state or
other jurisdiction, where the offer, solicitation or sale of these
securities would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter,
YouTube
and Facebook.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb’s
business, particularly those identified in the cautionary factors
discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the
year ended December 31, 2016 in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170222006673/en/